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Abstract: One hundred and four male patients hospitalized for the first time with the diagnosis
of first-episode schizophrenia were comprehensively assessed on admission and discharge.
Psychopathology, treatment response, and remission rates were evaluated (based on the Positive
and Negative Syndrome Scale (PANSS), severity of symptoms only). On admission, the most
frequently observed symptoms were lack of judgment and insight (87.6%), suspiciousness/
feelings of persecution (82.3%), delusions (77%), poor attention (70%), disturbance of volition
(65.4%), conceptual disorganization (64.7%), and active social avoidance (64%). Except for
delusions and hallucinations, the positive items of the PANSS correlated significantly with
negative symptoms, and conceptual disorganization correlated with the greatest number of
negative symptoms. Individual negative symptoms were present in about half the patients. At
discharge, the most frequent symptoms were again lack of judgment and insight (in 55.7%),
and for negative symptoms they were blunted affect (22.1%), emotional withdrawal (21.2%),
and passive/apathetic social withdrawal (19.5%). The positive symptoms of suspiciousness/
feelings of persecution and grandiosity persisted in 20.6% of patients. On average, all symptoms
were significantly reduced 44 days after admission. The negative symptoms improved less,
compared with the positive ones. At discharge there was a high rate of responders (response
defined as minimal 30% reduction of total PANSS): 73% and 74% of patients fulfilled the
criteria for remission. On admission, the responders (n = 76) had significantly higher scores
of most symptoms, both positive and negative ones than nonresponders (n = 28).
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Introduction
Studying drug-naive, first-episode patients has several advantages, including the
opportunity to assess symptoms and signs of illness before the confounding effects
of treatment, which ultimately are difficult to disentangle from the effects of illness
progression. The investigation of responses to medication offers similar advantages.
The small number of clinical trials exploring first-episode schizophrenia leaves a
gap between evidence-based and practice-based management. The available data
indicate that in first-episode patients, positive symptoms, including hallucinations
and delusions, will most often remit with antipsychotic treatment. According to
Bradford et al (2003), estimates of the proportion of first-episode patients responding
to acute antipsychotic treatment vary from 29% to 96%. The variance in response
rates in these studies is related to a number of factors, but most importantly to the
duration of the antipsychotic trial, the definition of response, and the drug
administered.
The treatment of patients with first-episode schizophrenia has specific features.
Compared with later stages of the disease, the first episode is characterized by a
more pronounced drug response. Furthermore, both positive and negative symptoms
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improve. Low doses of antipsychotics, ie, 2–6 mg of
haloperidol or its equivalent, are effective and patients are
more sensitive to extrapyramidal side effects (Remington
et al 1998). Atypical antipsychotics represent a great advance
in the treatment of first-episode schizophrenia, as there is
strong evidence for greater tolerability with equal or better
therapeutic efficacy. Still, many patients optimally treated
with atypicals are not able to return to their premorbid
functioning and experience significant and persistent
morbidity.
The Department of Psychiatry of Brno has long-standing
experience with patients suffering from first-episode
schizophrenia. In addition to a detailed clinical evaluation
and a neurological examination focused on soft neurological
signs; endocrine, neuroanatomical, and functional brain
parameters are monitored and cognitive dysfunction is
evaluated (C °ešková et al 2002). This article reports the
results of the response of patients with first-episode
schizophrenia to treatment based on the psychopathology
of the initial treatment phase. The objectives of the study
were: (1) to assess in detail the psychopathology before and
after the acute antipsychotic treatment; and (2) to evaluate
the response to short-term treatment.
Methods
Subjects
Male patients consecutively hospitalized between November
1997 and March 2004 in the psychotic ward of the
Department of Psychiatry were included if they: (1) were
experiencing their first admission for first-episode
schizophrenia (according to ICD-10); (2) provided written
informed consent; and (3) were drug-naive or had a
maximum of four weeks of cumulative exposure to
antipsychotic treatment before admission. The exclusion
criteria included a history of drug abuse, evidence of organic
brain disorder including mental retardation, severe somatic
disease, or premature discharge before completing inpatient
treatment. The history of previous psychopharmacological
treatment was carefully documented in interviews with each
patient and the patients’ relatives.
ICD-10 diagnoses were made on the basis of a
comprehensive assessment of symptoms and history and
all other available information about the patients. The
diagnosis was confirmed by consensus of two psychiatrists
during separate interviews.
Clinical assessment
The psychic state of the patients using the Positive and
Negative Syndrome Scale (PANSS; Kay et al 1987) was
evaluated after admission (before treatment) and at
discharge. Patients meeting inclusion criteria completed a
semistructured interview for PANSS with two of the authors
(RP and MO rated approximately half the patients each).
High interrater reliability for clinical assessment was
repeatedly confirmed during raters’ participation in
international multicenter clinical trials and in regular training
sessions at the psychiatric department performed by a skilled
clinical researcher (first author EC). The study was designed
as an open study. The patients’ psychopathology was
evaluated on admission, before they started antipsychotic
treatment, and on discharge. The response rate (defined as
minimally 30% reduction from baseline in the PANSS total
score) and achievement of symptomatic remission was also
evaluated on discharge. The criteria used were PANSS
based, including only severity not duration. The score of 3
(mild) or less was required on all eight of the following
PANSS items: P1 delusions, P2 conceptual disorganization,
P3 hallucinatory behaviour, G5 mannerisms and posturing,
G9 unusual thought content, N1 blunted affect, N4
passive/apathetic social withdrawal, and N6 lack of
spontaneity and flow of conversation (Kane 2003).
Treatment
Following baseline assessment on admission, all patients
were treated openly by monotherapy with an antipsychotic
chosen by the patient’s treating clinician. Since becoming
available in the Czech Republic, risperidone has been the
first drug choice. Other choices were made according to
clinical judgment and drug availability. The only concomi-
tant treatments allowed were benzodiazepines for tension,
anxiety, and insomnia, and biperidene for extrapyramidal
symptoms. The medication was administered by psychiatric
nurses to ensure medication adherence.
Data analysis
The statistical analysis was made by comparison of sample
means (the paired t-test for comparison of data after
admission and before discharge, and t-test for comparison
of responders and nonresponders). For correlations between
the positive and negative symptoms the Spearman
correlation coefficient was used.Neuropsychiatric Disease and Treatment 2005:1(2) 181
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Results
Study sample
The study included 104 male inpatients suffering from first-
episode schizophrenia according to ICD-10. Their average
age was 23.3 (SD 5.7) years. The mean duration of index
hospitalization was 44.5 (SD 15.3) days. The mean length
of illness, determined from the time the patients first
exhibited illness-related behavioral symptoms, was 0.77
(SD 1.0) years. Twenty-eight patients were treated with
classical antipsychotics, 64 with risperidone, and 12 with
other second generation antipsychotics (atypicals). The
mean dose of risperidone was 3.7 (SD 1.2) mg or 218.4
(SD 93) mg chlorpromazine equivalents daily (Woods 2003).
Psychopathology and treatment
responsiveness
Psychopathology on admission, discharge, and during
treatment is shown in Table 1. Scores for all symptoms
decreased significantly before discharge, on average 44 days
after admission. We identified 76 responders and 28
nonresponders.
In a categorical analysis of response rate, the proportion
of study subjects responding at discharge was 73%; and
74% of patients fulfilled the criteria of remission.
On admission, responders compared with nonresponders
had significantly higher scores of 21 individual items out
of 30 items (NS difference, P3 hallucinatory behavior, P5
Table 1 Psychopathology according to the PANSS in patients with first-episode schizophrenia (n = 104)
Admission Discharge
Admission Discharge  presence  presence
Measure mean SD mean SD p-values (%) (%)
P1 delusions 4.5 1.7 1.6 0.9 < 0.001 77.0 9.7
P2 conceptual disorganization 3.9 1.5 1.8 1.0 < 0.001 64.7% 13.3
P3 hallucinatory behavior 3.5 1.8 1.2 0.6 < 0.001 59.3 9.7
P4 excitement 2.5 1.6 1.2 0.6 < 0.001 28.3 8
P5 grandiosity 1.9 1.4 1.3 0.7 < 0.001 25.7 20.6
P6 suspiciousness/persecutions 4.4 1.2 2.1 0.9 < 0.001 82.3 20.6
P7 hostility 1.8 1.3 1.1 0.3 < 0.001 16.8 8
Positive subscale PANSS  22.5 6.5 10.3 3.3 < 0.001
N1 blunted affect 3.3 1.5 2.6 1.0 < 0.001 44.3 22.1
N2 emotional withdrawal 3.8 1.4 2.6 1.0 < 0.001 62 21.2
N3 poor rapport 3.6 1.6 2.4 1.1 < 0.001 46 15.9
N4 passive/apathetic social withdrawal 3.8 1.6 2.5 1.1 < 0.001 57.5 19.5
N5 difficulty in abstract thinking 4.2 1.8 2.4 1.2 < 0.001 64.6 17:7
N6 lack of spontaneity and flow of conversation 3.5 1.7 2.2 1.1 < 0.001 52.2 14.1
N7 stereotyped thinking 3.9 1.4 2.4 1.0 < 0.001 64.6 18.6
Negative subscale PANSS 26.1 8.8 17.2 6.0 < 0.001
G1 somatic concern 2.6 1.8 1.7 0.9 < 0.001 31.8 11.5
G2 anxiety 2.9 1.5 1.4 0.8 < 0.001 38 8.8
G3 guilt feelings 1.9 1.3 1.4 0.9 0.0038 24.8 12.4
G4 tension 2.8 1.4 1.4 0.7 < 0.001 27.4 8.8
G5 mannerisms and posturing 2.3 1.4 1.6 1.0 < 0.001 23.9 11.5
G6 depression 2.4 1.4 1.8 1.0 < 0.001 30 14.2
G7 motor retardation 2.6 1.5 2.2 1.0 0.014 37.2 17.7
G8 uncooperativeness 2.7 1.8 1.2 0.6 < 0.001 32.8 8.8
G9 unusual thought content  3.5 1.3 1.8 0.8 < 0.001 53.0 8
G10 disorientation 2.0 1.4 1.0 0.3 < 0.001 27.4 8
G11 poor attention 4.1 1.2 2.6 0.8 < 0.001 70 15
G12 lack of judgment and insight 4.8 1.3 3.4 1.0 < 0.001 87.6 55.7
G13 disturbance of volition 3.8 1.2 2.6 1.0 < 0.001 65.4 21.2
G14 poor impulse control 1.9 1.3 1.1 0.4 < 0.001 19.9 8
G15 preoccupation 3.8 1.4 2.3 1.0 < 0.001 60 15.9
G16 active social avoidance 3.7 1.4 2.2 1.0 < 0.001 64 11.5
General subscale PANSS 48.1 11.7 30.0 8.0 < 0.001
Total score PANSS 96.7 22.4 57.6 15.1 < 0.001
NOTE: symptom presence – score minimally 4 for individual items; NS – significant level > 0.1.
Abbreviations: PANSS, Positive and Negative Syndrome Scale.Neuropsychiatric Disease and Treatment 2005:1(2) 182
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grandiosity, P7 hostility, G1 somatic concern, G2 anxiety,
G3 guilt feelings, G4 tension, G6 depression, G7 motor
retardation). Conversely, at discharge the nonresponders had
significantly higher scores of individual symptoms with the
exception of P4 excitement, P5 grandiosity, P7 hostility, G3
guilt feelings, G5 mannerisms and posturing, and G14 poor
impulse control; ie, the significantly higher psychopathology
was observed in 25 out of 30 items (see Table 2).
Association between positive and
negative symptoms
Delusions and hallucinations did not correlate significantly
with negative symptoms. A significant positive correlation
was found between conceptual disorganization and
emotional and social withdrawal, poor rapport, difficulty in
abstract thinking, and lack of spontaneity and stereotyped
thinking. Significant negative correlation was found between
excitement and blunted affect, and emotional and social
withdrawal; and significant positive correlation was found
between excitement, difficulty in abstract thinking, and
stereotyped thinking. Significant negative correlation was
observed between grandiosity and blunted affect and lack
of spontaneity; and positive correlation was observed
between grandiosity and difficulty in abstract thinking.
Suspiciousness and hostility correlated significantly with
difficulty in abstract and stereotyped thinking, and hostility
correlated significantly with poor rapport (see Table 3).
Table 2 Comparison of symptoms in responders and nonresponders (mean values)
Admission Discharge
Responder Nonresponder Responder Nonresponder
Measure mean SD mean SD p-values mean SD mean SD p-values
n7 6 2 8 7 6 2 8
P1 delusions 4.8 1.8 4.0 1.4 0.0445 1.5 0.8 2.1 1.0 0.0026
P2 conceptual disorganization 4.3 1.4 2.9 1.2 < 0.001 1.6 0.8 2.4 1.1 < 0.001
P3 hallucinatory behavior 3.7 1.8 3.0 1.7 NS 1.1 0.3 1.6 0.9 < 0.001
P4 excitement 2.7 1.7 1.8 1.0 0. 0186 1.1 0.5 1.4 0.8 NS
P5 grandiosity 2.0 1.5 1.5 1.0 NS 1.2 0.6 1.5 1.0 NS
P6 suspiciousness/persecutions 4.5 1.2 3.9 1.0 0.0223 1.9 0.8 2.6 0.9 < 0.001
P7 hostility 1.9 1.4 1.5 0.7 NS 1.0 0.3 1.2 0.4 NS
Positive subscale PANSS  24.0 6.6 18.6 3.4 < 0.001 9.4 2.5 12.7 3.9 < 0.001
N1 blunted affect 3.5 1.6 2.6 1.1 0.005 2.3 1.0 3.2 0.8 < 0.001
N2 emotional withdrawal 4.0 1.6 3.2 0.8 0.0223 2.4 1.0 3.3 0.6 < 0.001
N3 poor rapport 4.0 1.7 2.6 0.8 < 0.001 2.1 1.0 3.2 1.0 < 0.001
N4 passive/apathetic social withdrawal 4.0 1.6 3.2 1.1 0.0160 2.2 1.0 3.2 0.9 < 0.001
N5 difficulty in abstract thinking 4.7 1.8 3.0 1.4 < 0.001 2.2 1.2 2.9 1.0 0.0059
N6 lack of spontaneity and flow of
conversation 3.8 1.8 2.7 1.1 0.0036 2.0 1.0 2.8 1.2 0.0022
N7 stereotyped thinking 4.1 1.5 3.3 0.9 0.0135 2.1 0.9 3.2 0.7 < 0.001
Negative Subscale PANSS 28.1 9.1 20.6 4.8 < 0.001 15.6 5.5 21.8 4.5 < 0.001
G1 somatic concern 2.8 2.0 2.1 1.0 NS 1.5 0.9 2.0 1.0 0.0228
G2 anxiety 2.9 1.6 2.8 1.1 NS 1.3 0.7 1.7 1.0 0.0163
G3 guilt feelings 1.9 1.4 1.8 1.2 NS 1.4 0.8 1.6 1.2 NS
G4 tension 2.9 1.5 2.5 1.1 NS 1.3 0.6 1.7 0.9 0.0068
G5 mannerisms and posturing 2.5 1.4 1.7 1.0 0.0112 1.5 0.9 1.9 1.0 NS
G6 depression 2.4 1.5 2.5 1.4 NS 1.6 0.9 2.2 1.1 0.0061
G7 motor retardation 2.6 1.6 2.8 1.1 NS 2.0 1.0 2.7 0.9 < 0.001
G8 uncooperativeness 3.0 2.0 1.7 0.9 0.0014 1.1 0.4 1.5 0.8 0.0052
G9 unusual thought content  3.8 1.3 2.9 1.0 0.0019 1.7 0.8 2.2 0.8 0.0059
G10 disorientation 2.2 1.5 1.3 1.1 0.0045 1.0 0.0 1.2 0.5 0.0050
G11 poor attention 4.5 1.2 3.4 0.7 < 0.001 2.5 0.8 3.0 0.7 0.0020
G12 lack of judgment and insight 5.1 1.3 4.2 1.0 0.0037 3.3 1.0 3.8 0.8 0.0078
G13 disturbance of volition 4.0 1.2 3.2 1.1 0.0042 2.3 0.9 3.1 1.1 < 0.001
G14 poor impulse control 2.1 1.4 1.4 0.7 0.0145 1.1 0.4 1.2 0.6 NS
G15 preoccupation 4.1 1.4 3.0 1.0 < 0.001 2.1 0.9 3.0 0.8 < 0.001
G16 active social avoidance 4.0 1.5 3.0 0.9 0.0016 2.0 0.8 2.8 0.8 < 0.001
General subscale PANSS 51.0 11 40.4 7.6 < 0.001 27.8 6.6 35.9 8.2 < 0.001
Total Score PANSS 103.1 22 79.7 12.6 < 0.001 52.7 12 70.6 14.2 < 0.001
NOTE: symptom presence–score minimally 4 for individual items; NS – significant level > 0.1.
Abbreviations: Resp responders; nonresp, nonresponders; PANSS, Positive and Negative Syndrome Scale.Neuropsychiatric Disease and Treatment 2005:1(2) 183
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Discussion
This study is unique in its detailed evaluation of individual
symptoms in patients experiencing first-episode
schizophrenia. Observed psychopathology on positive
subscale of PANSS at the initial assessment demonstrated
the highest occurrence of suspiciousness/feelings of
persecutions (82.3%), delusions (77%), conceptual
disorganization (64.7%), and hallucinatory behavior
(59.3%). Excitement, grandiosity and hostility were less
frequent. All negative symptoms were present in about half
the patients. The negative symptoms present in first
hospitalized, drug-naive patients could be considered as
primary negative symptoms (Peralta et al 2000). In a
methodologically sound study, Peralta came to the
conclusion, that negative symptoms rated during a first
psychotic episode before and after starting antipsychotic
treatment are mainly primary in character, and should be
considered as a direct manifestation of the basic dysfunctions
of schizophrenia. The high scores of negative symptoms,
although it exceeds numerically the positive symptom score,
is comparable with previously published studies that
assessed symptoms by means of the PANSS and gave initial
values (Sanger et al 1999; Oosthuizen et al 2004). In our
sample, the most frequent general symptoms were lack of
judgment and insight (87.6%), poor attention (70%),
disturbance of volition (65.4%), active social avoidance
(64%), preoccupation (60%), and unusual thought content
(53%). Overall, the most frequently observed symptoms
after admission were lack of judgment and insight and
suspiciousness/feelings of persecutions.
At discharge, lack of judgment and insight was present
in 55.7% of patients. As for negative symptoms, blunted
affect was present in 22.1% of patients, emotional
withdrawal in 21.2%, and passive/apathetic social
withdrawal in 19.5% of patients. As for positive symptoms,
suspiciousness/feelings of persecutions persisted in 20.6%
and grandiosity in 20.6% of patients. The high percentage
of patients with lack of judgment and insight could
contribute to the well known fact that patients with first-
episode schizophrenia are highly noncompliant. Coping with
first-episode schizophrenia may be similar to that seen in
patients with serious somatic diseases, where denial is one
of the first phases. Despite a favorable acute response profile,
first-episode patients have been shown to experience a high
rate of psychotic relapse, particularly if they have
discontinued antipsychotic medication (Gitlin et al 2001).
As for the treatment response, our results are consistent
with those of prior studies of patients with first-episode
schizophrenia that have found favorable rates of therapeutic
response to antipsychotic drugs. In our sample a statistically
significant improvement of both positive and negative
symptoms was observed, but the reduction was less marked
for negative symptoms. Most studies of first-episode
schizophrenia report that the reduction of positive symptoms
is faster and more complete, and negative symptoms usually
persist in a mild form (Remington et al 1998; Bradford et al
2003; Oosthuizen et al 2004). The influence on negative
symptoms in studies with the same acute treatment duration
(6 weeks) was minor compared with the influence on
positive symptoms and it was comparable with our results.
The mean dose used in our patients is in agreement with
observations suggested that first-episode patients may be
more sensitive to the pharmacologic effects of antipsychotic
drugs and may thus require lower drug doses (McEvoy et al
1991; Remington et al 1998).
In a categorical analysis of the response rate, in a
6-week, randomized, controlled trial comparing the effects
of risperidone with those of haloperidol, the response rates
were 63% for risperidone and 56% for haloperidol (Emsley
1999). In another double-blind, 6-week acute treatment
Table 3 Correlations between positive and negative symptoms (Spearman correlation)
N6
N4 N5 lack of
N1 N2 N3 passive/apathetic difficulty spontaneity N7
blunted emotional poor social in abstract and flow of stereotyped
affect withdrawal rapport withdrawal thinking conversation thinking
P1 delusions –0.05 –0.11 –0.06 –0.07 0.14 –0.07 0.04
P2 conceptual disorganization 0.13 0.21a 0.46a 0.23a 0.62a 0.29a 0.56a
P3 hallucinatory behavior –0.01 0.08 0.10 0.05 0.00 0.09 0.02
P4 excitement –0.34
a –0.24
a –0.01 –0.24
a 0.41
a –0.16 0.21
a
P5 grandiosity –0.25a –0.08 –0.09 –0.16 0.23a –0.21a 0.07
P6 suspiciousness/persecutions –0.02 0.17 0.18 0.17 0.24
a 0.11 0.30
a
P7 hostility –0.17 0.12 0.28
a 0.15 0.34
a 0.18 0.24
a
a p < 0.05Neuropsychiatric Disease and Treatment 2005:1(2) 184
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study comparing olanzapine and haloperidol, the rate of
clinical response was significantly higher for the olanzapine-
treated patients (67.2%) than for the haloperidol-treated
patients (29.2%) (Sanger et al 1999). A recently published
study comparing clozapine and chlorpromazine in patients
with first-episode schizophrenia and schizophreniform
disorder reported response rates of 62% for clozapine and
50% for chlorpromazine (Lieberman, Phillips, et al 2003).
Finally, in a double blind study the proportion of study
subjects responding by week 12 was 55% for those assigned
to olanzapine, compared with 46% for those receiving
haloperidol (Lieberman, Tollefson, et al 2003). The response
rate in the present study was 73%. The difference may be
explained by the sample characteristics and methods. In the
present sample, mostly drug-naive patients were included,
the study was open, and medications were individualized
with the potential to change the antipsychotic according to
the psychic state. Although the response criteria of all these
studies varied, overall the results indicate that patients with
first-episode psychosis are highly responsive to anti-
psychotic drug treatment, with a trend suggesting that
atypical drugs exhibit some degree of superiority over
typicals in response rate and time to response. Most of our
patients were also treated with atypical antipsychotics. Our
expectations of treatment outcomes for patients are evolving.
Remission is now a realistic goal. Patients in symptomatic
remission will benefit most from psychosocial interventions.
A substantial part of our patients fulfilled not only the
response criteria but also suggested criteria for remission.
In responders we found a significantly higher score on
both positive and negative symptoms before treatment
including the lack of judgment and insight. Responders had
higher scores of initial psychopathology than nonresponders.
A marked improvement in responders probably enabled
them to understand better that the previous condition had
been pathological and they experienced a clear difference
between the previous condition and the outcome of acute
treatment, thus improving their chance of creating insight.
Also the symptoms associated with the cognitive function
level (attention, thinking) improved more significantly and
they were able to understand better their own personal
realities. In the literature, the severity of basal sympto-
matology and the early change of symptomatology were
considered to be predictors of treatment response. But no
single factor was a strong prediction factor. A combination
of the factors seemed to be more promising (Awad et al
1994; C °ešková et al 2002). Of interest is also the association
between conceptual disorganization and negative symptoms.
Possibly, marked disorganization of thinking leads to
problems in the contact with reality and in communication.
We have not found any study that deals with such aspects
of first-episode schizophrenia.
The findings are limited by the fact that the study was
open and performed under routine clinical conditions. Not
all patients were treated according to the standard algorithm.
However, our results provide a closer look at the
psychopathological profile of patients with first-episode
schizophrenia and confirm that at this stage of illness there
is a capacity for early and substantial improvement of
symptoms. The persistent lack of judgment and insight in
about half of patients is a challenge for health professionals
and calls for early psychological care and alleviation of
psychotic symptoms.
Conclusions
On average there is a broad spectrum of psychopathology,
positive, (primary) negative, and less specific general
symptoms present in most patients with first-episode
schizophrenia. Despite patients reacting quickly to
antipsychotic treatments, some symptoms (lack of judgment
and insight, negative symptoms) persist in some patients
and may contribute to function impairment and non-
compliance. Patients with severe psychopathology may be
more responsive to the acute treatment. Psychiatrists should
especially try to influence lack of judgment and insight,
which in the early stages of illness are important for its
future course.
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